Skip to main content
Premium Trial:

Request an Annual Quote

Applied Imaging Shareholders OK Acquisition by Genetix

NEW YORK (GenomeWeb News) — Applied Imaging shareholders have approved the sale of the company to Genetix Group, AI said today.
 
As GenomeWeb News reported when the acquisition was announced in September, the all-cash deal is valued at $25.8 million. Genetix will pay $4.20 for each share of Applied Imaging's common stock.
 
Since announcing the deal, Genetix has raised its original bid price of $3.03 several times in response to unsolicited bids by at least one third-party to purchase Applied Imaging.
 
The companies did not say when they expect the deal to close.

This article originally appeared in ProteoMonitor, a GenomeWeb News sister publication.
The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.